An observational study in Pancreatic Cyst and Molecular, Chemical Analysis of Cystic Fluid, sponsored by Seoul National University Hospital. Recruiting at 1 site in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-12.
Sponsored by Seoul National University Hospital · Observational
Through a comprehensive analysis of the pancreatic cystic fluid analysis, the role of the cystic fluid analysis is confirmed in terms of accurate diagnosis of pancreatic cysts, appropriate prediction of treatment response, and to select proper treatment indication through analytic results.
94 studies on the registry are indexed under Pancreatic Cyst; 34 are open to participants now.
This study's planned enrollment of 500 is above the median of 300 across 50 observational studies indexed under Pancreatic Cyst.
Browse Pancreatic Cyst studies →Seoul National University Hospital is the lead sponsor of 1,860 studies on the registry; 275 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
Counted across the registry records on this site, refreshed daily.
patients who were diagnosed with pancreatic cystic lesions and managed in Seoul National University Hospital
Exclusion Criteria:
diagnostic accuracy by cystic fluid analysis
diagnostic accuracy by cystic fluid analysis in comparison with pathologic diagnosis
Time frame: up to 5 years after cystic fluid analysis
Overall survival
overall survival until death
Time frame: up to 5 years after cystic fluid analysis or surgical resection
Disease free survival
Period till tumor recurrence after surgical resection or intervention
Time frame: up to 5 years after cystic fluid analysis or surgical resection
Malignant transformation rate
the prevalence of malignant transformation during follow-up period (percent)
Time frame: up to 5 years after cystic fluid analysis
Prediction for treatment response in case of surgical resected or EUS-guided ethanol ablated pancreatic cysts
evaluation of treatment response for surgery of EUS guided therapy according to RECIST criteria v1.1
Time frame: up to 5 years after cystic fluid analysis or EUS guided ablative therapy
Cytology of cystic fluid
result of cytology of cystic fluid
Time frame: within 2 months after study enrollment
Chemical profile of CEA in cystic fluid
level of CEA in cystic fluid
Time frame: within 2 months after study enrollment
Chemical profile of Amylase in cystic fluid
level of amylase in cystic fluid
Time frame: within 2 months after study enrollment
Chemical profile of glucose in cystic fluid
level of glucose in cystic fluid
Time frame: within 2 months after study enrollment
DNA mutation profile of cystic fluid
targeted NGS for KRAS, NRAS, CDKN2A, TP53, SMAD4, RNF43, PTEN, PIK3CA, VHL, Aneuploid
Time frame: within 2 months after study enrollment
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National University Hospital